Bank of New York Mellon’s Cogent Biosciences COGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$20.7M Buy
533,968
+161,172
+43% +$5.64M ﹤0.01% 1603
2026
Q1
$14.3M Sell
372,796
-3,500
-0.9% -$129K ﹤0.01% 1719
2025
Q4
$13.4M Buy
376,296
+13,280
+4% +$373K ﹤0.01% 1757
2025
Q3
$5.21M Buy
363,016
+71,225
+24% +$844K ﹤0.01% 2288
2025
Q2
$2.1M Buy
291,791
+35,191
+14% +$195K ﹤0.01% 2716
2025
Q1
$1.54M Sell
256,600
-2,166
-0.8% -$17K ﹤0.01% 2809
2024
Q4
$2.02M Sell
258,766
-4,812
-2% -$48K ﹤0.01% 2759
2024
Q3
$2.85M Sell
263,578
-63,006
-19% -$613K ﹤0.01% 2585
2024
Q2
$2.75M Buy
326,584
+45,770
+16% +$347K ﹤0.01% 2618
2024
Q1
$1.89M Sell
280,814
-20,085
-7% -$124K ﹤0.01% 2791
2023
Q4
$1.77M Buy
300,899
+12,692
+4% +$97.3K ﹤0.01% 2895
2023
Q3
$2.81M Buy
288,207
+39,491
+16% +$468K ﹤0.01% 2612
2023
Q2
$2.94M Buy
248,716
+28,822
+13% +$331K ﹤0.01% 2620
2023
Q1
$2.37M Sell
219,894
-38,879
-15% -$497K ﹤0.01% 2704
2022
Q4
$2.99M Buy
258,773
+4,946
+2% +$61.3K ﹤0.01% 2624
2022
Q3
$3.79M Buy
+253,827
New +$3.48M ﹤0.01% 2447
2019
Q2
Sell
-13,251
Closed -$232K 4223
2019
Q1
$232K Buy
13,251
+1,689
+15% +$28.9K ﹤0.01% 3834
2018
Q4
$204K Buy
11,562
+8,273
+252% +$245K ﹤0.01% 3845
2018
Q3
$135K Buy
3,289
+213
+7% +$12K ﹤0.01% 3995
2018
Q2
$177K Buy
+3,076
New +$148K ﹤0.01% 3928

Other funds holding COGT

Bank of New York Mellon's COGT Position: Q2 2026 in Review

Bank of New York Mellon increased its Cogent Biosciences (COGT) stake by 43% in Q2 2026, buying an estimated $5.64M and bringing the position to 533,968 shares worth $20.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1603.

Bank of New York Mellon first reported a position in COGT in Q2 2018 and has held it in 20 quarters since. 112 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Bank of New York Mellon held 533,968 shares of Cogent Biosciences worth $20.7M as of Q2 2026.
  • Bank of New York Mellon bought 161,172 Cogent Biosciences shares in Q2 2026, an estimated $5.64M.
  • Cogent Biosciences made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1603 holding.
  • Bank of New York Mellon first reported a position in Cogent Biosciences in Q2 2018 and has held it in 20 quarters since.
  • 112 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.